Better Therapeutics, Inc.
BTTX
$0.0002
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.34% | 10.49% | 42.80% | 96.19% | 266.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.57% | -11.92% | 2.50% | 25.20% | 110.49% |
| Operating Income | 29.57% | 11.92% | -2.50% | -25.20% | -110.49% |
| Income Before Tax | 29.68% | 19.24% | 11.69% | 1.82% | -58.84% |
| Income Tax Expenses | -- | 400.00% | 500.00% | 104.58% | 100.00% |
| Earnings from Continuing Operations | 29.66% | 19.22% | 11.67% | 1.43% | -59.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.66% | 19.22% | 11.67% | 1.43% | -59.23% |
| EBIT | 29.57% | 11.92% | -2.50% | -25.20% | -110.49% |
| EBITDA | 32.00% | 13.54% | -1.56% | -22.98% | -111.80% |
| EPS Basic | 40.97% | 44.45% | 46.28% | 47.70% | 26.33% |
| Normalized Basic EPS | 42.75% | 44.93% | 47.08% | 48.10% | 22.46% |
| EPS Diluted | 40.97% | 44.45% | 46.28% | 47.70% | 26.33% |
| Normalized Diluted EPS | 42.75% | 44.93% | 47.08% | 48.10% | 22.46% |
| Average Basic Shares Outstanding | 29.76% | 32.33% | 46.88% | 82.13% | 59.20% |
| Average Diluted Shares Outstanding | 29.76% | 32.33% | 46.88% | 82.13% | 59.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
